Drug monitoring of omalizumab in treatment of 2 children with high level IgE allergic asthma
10.12206/j.issn.1006-0111.202205109
- VernacularTitle:奥马珠单抗治疗2例高水平IgE过敏性哮喘患儿的用药监护
- Author:
Na ZENG
1
;
Chao WANG
1
;
Huajun SUN
1
;
Liping MA
2
;
Xiaoyan DONG
1
Author Information
1. Shanghai Children’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200062, China.
2. Shanghai East Hospital, Shanghai 200120, China.
- Keywords:
omalizumab;
children;
allergic asthma;
high level IgE;
efficacy;
adverse reaction
- From:
Journal of Pharmaceutical Practice
2022;40(4):368-371
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and safety of the omalizumab treatment in children with high level IgE allergic asthma. Methods The clinical data of 2 children with allergic asthma treated with omalizumab in the Departemnt of Respiratory Medicine of Shanghai Children’s Hospital from August 2020 to May 2021 were retrospectively analyzed, and they had regular follow-up after end of treatment. The dosage and course of treatment, therapeutic effect and adverse drug reactions of omalizumab were analyzed. Results After receiving omalizumab treatment, asthma symptoms were well controlled, the dosage of inhaled corticosteroids during asthma treatment were reduced and nasal symptoms were relieved. 20 subcutaneous injections were received by 2 children, and no adverse reactions were found. After the treatment, regular pharmaceutical follow-up showed that the children were in good health. Conclusion Omalizumab is suitable for high level IgE allergic asthma and can improve asthma control symptoms with good long-term safety. However, the appropriate dosage and course of treatment still need further experience accumulation.
